The FDA has approved the ALK inhibitor alectinib for surgically resectable NSCLC. The U.S. Food and Drug Administration (FDA) has approved alectinib (Alecensa) for use after the surgical removal of a non-small cell lung...
Researchers at the AACR Annual Meeting 2024 presented the latest findings regarding two personalized neoantigen cancer vaccines.
A poster at the AACR Annual Meeting 2024 examined a video that increased awareness of prostate cancer.
More cancer patients are enrolling in clinical trials, and sentinel node biopsies alone may be adequate for some early-stage breast cancers.
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu) for adult patients with unresectable...
The recently approved immunotherapy Amtagvi uses a patient’s own immune cells to destroy advanced melanoma.
March's picks include how synergy drives drug resistance in AML, new early detection tools, and more.
First CAR T-cell therapy approval in chronic lymphocytic leukemia, and Environmental Protection Agency announces a complete ban on asbestos use in manufacturing.
Mirvetuximab soravtansine-gynx was approved for certain ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved mirvetuximab soravtansine-gynx (Elaher) for patients with ovarian epithelial, fallopian tube, or peritoneal cancers...
Three patients share their experiences about having Lynch syndrome.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More